CRV431 is a non-immunosuppressive analog of cyclosporine A (CsA) whose primary biochemical action is inhibition of cyclophilin isomerase activity, playing a key role in protein folding. Other viruses such as HIV-1 and HCV, similarly use cyclophilin for their replication. In pre-clinical studies, CRV431 has shown potential in experimental models to complement current hepatitis B treatments by reducing multiple markers of infection including HBV DNA, HBsAg, HBeAg, and HBV uptake by cells. Studies have also demonstrated that CRV431 reduces the progression of fibrosis in an animal model and also reduces both the number and size of liver tumors in a hepatocellular carcinoma (HCC) model.  CRV431 is currently the subject of a Phase 1 clinical trial testing clinical safety and efficacy in healthy volunteers and HBV patients.

Potential Advantages of CRV431

HBV-Optimized Cyclosporine A Derivative (Non-Immunosuppressive)
  • Positioned to be leading host-targeting cyclophilin inhibitor (CPI)
Strong Drug Profile
  • Best-in-class potency against HBV
  • Widest selective index of any known CPI
Addresses Key HBV Endpoints
  • Inhibits viral entry
  • Reduces intracellular HBV DNA
  • Reduces HBsAg, pgRNA and HBeAg
  • May prevent liver disease progression (e.g. fibrosis, HCC)